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Abstract
Background: As part of the EU funded project “HEPscreen”, the aim of this study is to identify hepatitis B and C
screening and patient management guidelines, to assess the awareness of these among health professionals (HPs)
and to explore the availability of hepatitis B/C training programmes for HPs in Germany, Italy, the Netherlands, the
UK, Spain and Hungary.
Methods: A comprehensive literature search through the main scientific databases was performed to retrieve
guidelines, following which an online survey was developed and sent to HPs in six areas of health care, including
public health, to verify whether HPs are aware of these guidelines, to retrieve additional guidelines and to find out
whether specific professional training is available.
Results: Twelve national guidelines were identified through the literature search. Of the 268 respondents, 80 %
were aware of hepatitis B guidelines and 73 % were aware of hepatitis C guidelines in their country. The national
guidelines identified through the literature search were mentioned by 1/3 of HPs in the UK and Germany, 13 % of
HPs in the Netherlands, 14 % in Italy and 4 % in Spain. An additional 41 hepatitis B/C related guidance documents
were retrieved through the online survey: 15 in the UK, seven in Hungary, six in Italy, five in the Netherlands, four in
Germany and four in Spain. Availability of training programmes to improve skills and knowledge in viral hepatitis
was most often reported in the Netherlands, with 82 % indicating availability and just 10 % indicating no
availability, and least commonly in Italy, with 42 % indicating yes but 40 % indicating no. Availability was also
reported by the majority in the UK, Hungary and Spain, while in Germany the majority selected unsure.
Conclusions: Results suggest that the scientific databases are not the most important information source of best
clinical practice for many HPs. Implementation of best practices requires that guidelines are specifically designed
and actively promoted among those who are to follow them. Training can disseminate these best practice
recommendations and raise awareness of guidelines. It is therefore encouraging that diverse training about
hepatitis B/C is available to the different professional groups.
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Background
Chronic hepatitis B and C are leading causes of liver
cancer and are both important public health issues in
Europe. In the European Union (EU), some segments of
the population, such as migrants from areas where HBV
or HCV are endemic and people who inject drugs
(PWID), are disproportionately affected by these diseases
[1–4]. The prevalence in the general population varies
from 0.4 to 5.2 % for anti-HCV and from 0.1 to 5.6 %
for HBsAg [5]. However, also due to the largely silent
nature of these infections, reliable epidemiological data
in Europe are lacking both on HBV and HCV [6, 7] and
it has been estimated that up to 90 % of infected individ-
uals are undiagnosed [8]. Therefore, despite the exist-
ence of effective antiviral treatment that slows disease
progression and prevents the development of cirrhosis
and liver cancer, many patients who might benefit from
treatment remain undetected [9, 10]. Studies also allude
to ineffective counselling and referral of diagnosed
patients, as well as to the failure of chronically infected
patients to reach secondary care, leading to eligible viral
hepatitis patients being under-treated [11–16].
Informing health professionals (HPs) of evidence-based
recommendations on the prevention of hepatitis B and C,
the targeted screening of at-risk individuals, and the diag-
nostics and clinical management of patients with chronic
viral hepatitis, is crucial to obtain the best possible health
outcomes. The provision of comprehensive high quality
guidelines, as well as advanced training programmes to
improve the skills and knowledge of HPs on viral hepatitis
management, are ways to achieve this purpose. Numerous
studies, however, demonstrate little familiarity or low
compliance of HPs with guidelines summarising the best
available evidence in their specialties [17–21]. National
and European hepatitis B and C management guidelines
exist, however little is known about the extent to which
HPs who are to actually implement them are aware of
their existence. Similarly, little is known about the avail-
ability of in-service training on chronic viral hepatitis pre-
vention, diagnosis, management and treatment.
This study, conducted as part of EU HEPscreen, a
project co-funded by the EU Health Programme
(www.hepscreen.eu), has four specific aims. First, to
provide an overview of published hepatitis B and C
clinical practice guidelines available in Europe and in
particular in six EU countries with large migrant com-
munities and representation of migrant health and pa-
tient platform, i.e. the UK, Germany, the Netherlands,
Hungary, Italy and Spain. Second, to assess the awareness
of guidelines among HPs working in these six countries in
six fields: public health, antenatal care, primary care, care
for asylum seekers/refugees, sexual health, and gastro-
enterology/hepatology. Third, to measure the availability
of viral hepatitis specific training programmes for HPs in
these fields. Finally, to investigate HPs’ opinion on the ex-
istence of barriers such as limited guidance available to
primary health care professionals about onward referral,
counselling and patient management of hepatitis B/C pa-
tients and low training uptake among professionals as ex-
planations of why hepatitis B/C cases do not reach
specialized care for further investigation and treatment.
Methods
First, a comprehensive literature search was conducted to
retrieve published national and European hepatitis B and
C clinical guidelines. A modified version of the “PICO”
method [22] was applied, using a search syntax comprising
of four categories: (1) Population: “general population” OR
migrants OR “sex workers” OR “Intravenous drug users”
OR IDUs; (2) Disease: “hepatitis B” OR “hepatitis C”; (3)
Intervention: screening OR counselling OR referral OR
treatment OR therapies OR “clinical management”; (4)
Setting: Germany OR Hungary OR Italy OR Spain OR
the Netherlands OR the UK OR Europe. These four
categories were combined with “AND” to build the
final syntax. MEDLINE, EMBASE and the Cochrane
Library databases were searched. In addition, websites
of the National Institute for Health and Clinical Excel-
lence, the Scottish Intercollegiate Guidelines Network,
the Italian National Guidelines System, the European
Association for the Study of the Liver (EASL), the
European Centre for Disease Prevention and Control
(ECDC), the Robert‐Koch‐Institute, the World Health
Organization, the World Hepatitis Alliance, the European
Liver Patients Association and the Italian Liver Patient
Association, were searched. The literature search encom-
passed guidelines published between January 2000 to
March 2012 in English, Spanish, Italian, Dutch, Hungarian
or German and it was conducted between November 2011
and February 2012. Titles, abstracts and full-texts of
relevant documents were screened by two reviewers,
independently. Disagreements about eligibility were
resolved through discussion. A list of all guidelines re-
trieved was developed and categorised by country and
type of hepatitis.
To identify further professional guidelines missed by
the literature search and to assess awareness about exist-
ing guidelines among different groups of HPs involved
in screening for or caring for chronic viral hepatitis, six
semi-quantitative online surveys were developed. The
surveys were sent to HPs in their respective field i.e. to
public health professionals (PHPs); to general practi-
tioners (GPs); to sexual health service providers (SHS)
and/or genitourinary medicine (GUM) specialists; to ante-
natal care (ANC) providers; to asylum seeker care (ASC)
providers and to specialists (SP) in the field of gastro-
enterology/hepatology and infectious diseases. Each
survey was pilot tested, translated into the national
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language of the respective study countries, uploaded
into the open source online software package Lime-
Survey, and sent by e-mail to HPs in the six areas,
who were identified by board membership of clinical
associations, professional networks, ECDC focal
points, scientific literature and other means. Rather than
to reach a large representative sample of practising clini-
cians, the aim in each professional group was to reach 5–
10 HPs deemed able to reflect on the practice within their
specialism in general. Data were collected between July
and September 2012. Respondents agreed to participate
by answering the questionnaire.
We measured whether official national guidelines were
available, both general guidelines (the question was in-
cluded in all six surveys), with a request to provide the
title and publisher in a text field in case of a positive re-
sponse, and guidelines specifically developed for profes-
sionals in their field. We also asked public health
specialists whether specific guidelines for migrants from
endemic areas exist. The responses were exported into
SPSS 19.2 and a descriptive analysis was performed to
evaluate which hepatitis B/C guidelines are known to
HPs, how many professionals mentioned the main
guidelines identified through the literature search and
how many additional guidelines were retrieved. In all
surveys, except the survey aimed at public health
professionals, a question about the provision of hepatitis
B/C-related training for HPs in their respective medical
specialties was also included. The identification of gen-
eral hepatitis guidelines by respondents was analysed in
connection with their opinion on the existence of pro-
fessional training to improve knowledge and skills about
viral hepatitis. Finally, all professional groups were
asked to indicate on a five-point Likert scale, from
“strongly agree” to “strongly disagree", to which extent
they agree that the given statements are explanations of
why hepatitis B/C cases do not reach specialized health
care for further management: i) There is limited guidance
available to primary health care professionals about
onward referral, counselling and patient management
of hepatitis B/C patients; ii) Although training on viral
hepatitis management is available for health care pro-
viders, uptake is generally low among professionals.
The study complied with the Helsinki Declaration [23].
Results
Literature search results: clinical practice guidelines
The literature search retrieved eight international guide-
lines: two from EASL [24, 25]; two from the Association
for the Study of Liver Diseases [26, 27]; the “European
Guideline for the Management of Hepatitis B and C
Virus Infections” by the International Union against
Sexually Transmitted Infections [28]; the “Best Practice
in the Treatment of Chronic Hepatitis B” published by
the European Viral Hepatitis Educational Initiative [29];
and two National Institute of Health Consensus State-
ments on the management of hepatitis C and B from the
US [30, 31]. Twelve major national guidelines were re-
trieved: six in the UK [32–37], two in Italy [38, 39], two in
Germany [40, 41] and two in the Netherlands [42, 43].
Since the date of the search (March 2012), several
guidelines have been revised, mostly due to treatment
advances. In such cases, the updated guidelines are cited
as references.
Survey results
We received a total of 268 responses to the survey, not
evenly distributed across the six professional groups or
across the six countries (Table 1).
Identification of HBV and HCV guidelines through the
online survey
National or international guidelines already identified
through the literature search were mentioned by one third
of respondents in the UK and Germany, and only by a
minority of HPs in Italy (14 %) and the Netherlands (13 %)
and by just 4 % in Spain. An additional 41 hepatitis B/
C-related national guidance documents were identified by
HPs through the online survey: 15 in the UK, seven in
Hungary, six in Italy, five in the Netherlands, four in
Table 1 Number of health professionals completing the questionnaire by country and by survey
Survey (% of health professionals for each survey by country) Country Total
UK DE NL HU IT ES
Public health 9 (20 %) 13 (29 %) 7 (16 %) 2 (4 %) 8 (18 %) 6 (13 %) 45 (100 %)
Antenatal care 8 (10 %) 33 (40 %) 6 (7 %) 4 (5 %) 23 (28 %) 8 (10 %) 82 (100 %)
GP 8 (21 %) 4 (11 %) 9 (24 %) 1 (3 %) 14 (37 %) 2 (5 %) 38 (100 %)
Care for asylum seekers 4 (22 %) 3 (17 %) 4 (22 %) 3 (17 %) 3 (17 %) 1 (6 %) 18 (100 %)
SHS 9 (35 %) 4 (15 %) 7 (27 %) 3 (11 %) 1 (4 %) 2 (8 %) 26 (100 %)
Specialist care 9 (15 %) 7 (12 %) 22 (37 %) 8 (14 %) 9 (15 %) 4 (7 %) 59 (100 %)
Total 47 (18 %) 64 (24 %) 55 (21 %) 21 (8 %) 58 (22 %) 23 (9 %) 268 (100 %)
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Germany and four in Spain. Additional file 1 Table S1
compiles all hepatitis B/C related guidelines and guidance
documents retrieved through the literature search and/or
identified by HPs.
National general HBV and HCV screening and
management guidelines
The existence of official national general hepatitis B or
C screening and patient management guidelines in the
study countries, was reported by 61 % and 56 %,
respectively (Table 2). Among these, only about 40 %
provided the title and publisher of the guideline.
Around two thirds to three quarters of HPs in the
Netherlands and in Hungary reported availability of
general guidelines compared to just over half in the UK
and Italy. Conversely, the majority of HPs in Spain and,
for hepatitis C guidelines, in Germany, reported uncer-
tainty or that no general guideline is available.
Professional group-specific national HBV and HCV
guidelines
Overall 80 % (n = 215) of respondents are aware of
hepatitis B guidelines and 73 % (n = 196) of hepatitis C
guidelines in their country. Among the 45 PHPs,
around two thirds mentioned the existence of general
Hepatitis B and hepatitis C guidelines. Among the 38
GPs, 29 % mentioned specific HBV guidelines for GPs
and 21 % the existence of HCV guidelines for GPs.
Interestingly, among PHPs, 47 % mentioned the exist-
ence of HBV guidelines specifically for GPs and 40 %
the existence of GP-specific HCV guidelines. Of the 82
ANC experts, 52 % mentioned HBV and 26 % HCV
guidelines for antenatal services. Among the 59 second-
ary care specialists, 61 % mentioned HBV guidelines
and 56 % mentioned HCV guidelines. None of the 18
ASC experts identified the existence of HBV/HCV
guidelines for the care of asylum seekers. Just 22 % (for
HBV) and 13 % (for HCV) of PHPs reported the exist-
ence of specific guidelines for migrants from endemic
areas. Detailed results are displayed in Table 3.
Reported availability of hepatitis B/C training for health
care professionals
Table 4 shows the reported availability of training in the
six countries. Among secondary care specialists, avail-
ability of training was reported by 84 % (although only
by 44 % in Italy), among GPs by two thirds (although
only by half of them in Germany and Spain and by 40 %
in the UK) and by 55 % among SHS experts. Most HPs
working in antenatal care indicated that training is not
available or selected unsure. The majority opinion
among those providing care to asylum seeker is that
training is not available for professionals in their field.
Guidelines and Training
Availability of general national guidelines was most com-
monly mentioned by HPs who reported the existence of
professional training (Table 5). Over two thirds of those
who indicated that professional training is available also
indicated the existence of general guidelines for hepatitis
B (69 %) and hepatitis C (64 %), whereas among those
who indicated that training is not available, just 47 % for
HBV and 42 % for HCV reported the existence of general
national guidelines. Surprisingly, in Hungary, general
hepatitis B guidelines were identified more often by HPs
reporting a lack of, or uncertainty about, available training
for professionals.
Perceived barriers to inadequate referral of hepatitis B/C
cases
Limited guidance available to primary health care profes-
sionals about onward referral, counselling and patient
management of hepatitis B/C patients was perceived as
a reason of why hepatitis B/C patients do not reach
specialized health care for further investigation and
treatment according to nearly half of the respondents
in Italy (43 % answered they “agree” or “strongly agree”),
around a third of respondents in Spain, a quarter in the
UK and in Germany and a fifth in the Netherlands, but
not in Hungary (Table 6). Low training uptake among
Table 2 Health professionals reporting the existence of national general hepatitis B and C guidelines in their country
Hepatitis B guidelines UK (n = 47) DE (n = 64) NL (n = 55) HU (n = 21) IT (n = 58) ES (n = 23) Total (n = 268)
Proportion of health professionals
reporting the existence
57 % 56 % 78 % 67 % 57 % 43 % 61 %
Provided name and publishera 41 % 31 % 44 % 36 % 45 % 50 % 40 %
Hepatitis C guidelines UK (n = 47) DE (n = 64) NL (n = 55) HU (n = 21) IT (n = 58) ES (n = 23) Total (n = 268)
Proportion of health professionals
reporting the existence
60 % 47 % 67 % 67 % 57 % 39 % 56 %
Provided name and publisherb 39 % 37 % 51 % 29 % 45 % 44 % 42 %
aPercent of the respondents who reported the existence of general hepatitis B guidelines
bPercent of the respondents who reported the existence of general hepatitis C guidelines
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Table 3 Health professionals identifying hepatitis general or specific guidelines by professional group and by country
HBV GUIDELINES UK DE NL IT ES HU Total
General Hepatitis B guidelines
Public health professionals 56 % 77 % 71 % 50 % 67 % 100 % 67 %
Antenatal care experts 50 % 33 % 67 % 44 % 13 % 50 % 39 %
General Practitioners 38 % 50 % 78 % 71 % 100 % 100 % 66 %
Asylum seekers Experts 100 % 100 % 50 % 100 % 0 % 100 % 83 %
SHS Experts 56 % 75 % 86 % 100 % 0 % 67 % 65 %
Specialists 67 % 100 % 86 % 56 % 75 % 50 % 75 %
GP guidelines
Public health professionals 67 % 31 % 100 % 25 % 33 % 0 % 47 %
General Practitioners 13 % 0 % 78 % 21 % 0 % 0 % 29 %
Antenatal guidelines
Public health professionals 78 % 8 % 71 % 25 % 67 % 50 % 44 %
Antenatal care Experts 75 % 40 % 67 % 39 % 88 % 100 % 52 %
Asylum seekers guidelines
Public health professionals 33 % 0 % 14 % 13 % 0 % 0 % 11 %
Asylum seekers Experts 0 % 0 % 0 % 0 % 0 % 0 % 0 %
Specialists guidelines
Public health professionals 78 % 38 % 57 % 25 % 33 % 50 % 47 %
Specialists 44 % 43 % 86 % 33 % 75 % 50 % 61 %
Specific migrant care guidelines
Public health professionals reporting the existence
of specific migrant care guidelines
33 % 0 % 14 % 25 % 67 % 0 % 22 %
HCV GUIDELINES UK DE NL IT ES HU Total
General Hepatitis C guidelines
Public health professionals 56 % 77 % 57 % 50 % 67 % 100 % 64 %
Antenatal care experts 38 % 18 % 67 % 44 % 25 % 25 % 32 %
General Practitioners 38 % 50 % 67 % 71 % 50 % 100 % 61 %
Asylum seekers Experts 100 % 100 % 50 % 100 % 0 % 100 % 83 %
SHS Experts 67 % 75 % 71 % 100 % 0 % 67 % 65 %
Specialists 78 % 86 % 73 % 56 % 50 % 63 % 70 %
GP guidelines
Public health professionals 67 % 23 % 57 % 38 % 33 % 0 % 40 %
General Practitioners 0 % 0 % 56 % 21 % 0 % 0 % 21 %
Antenatal guidelines
Public health professionals 33 % 0 % 14 % 25 % 0 % 0 % 13 %
Antenatal care experts 25 % 13 % 0 % 35 % 75 % 25 % 26 %
Asylum seekers guidelines
Public health professionals 11 % 0 % 0 % 13 % 0 % 0 % 4 %
Asylum seekers Experts 0 % 0 % 0 % 0 % 0 % 0 % 0 %
Specialists guidelines
Public health professionals 56 % 23 % 29 % 25 % 0 % 0 % 27 %
Specialists 44 % 43 % 73 % 44 % 50 % 50 % 56 %
Specific migrant guidelines
Public health professionals reporting the existence
of specific migrant care guidelines
33 % 0 % 0 % 13 % 33 % 0 % 13 %
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professionals as a possible explanation was reported by
more than half of the respondents in Italy (54 % agreed or
strongly agreed with such a statement), by 38 % of those
in the UK, a third in the Netherlands, along with a sixth
in Germany in Hungary and 9 % in Spain (Table 6).
In Additional file 2, results in Tables 2–4 and 6 are
reported in absolute numbers.
Discussion
It has been estimated that in Europe only a minority of
hepatitis B or C cases are diagnosed, and that less than
20 % of infected individuals receive treatment [44]. The
reasons for the low treatment rate include on one hand
the largely silent nature of the disease, described accord-
ingly as “the silent epidemic”, which often prevents
Table 4 Availability of training to improve knowledge and skills in viral hepatitis in the six countries
UK GP (n = 10) Antenatal (n = 8) Asylum (n = 4) SHS (n = 10) Specialist (n = 10)
Yes 40 % 50 % 25 % 70 % 100 %
No 10 % 13 % 75 % 0 % 0 %
Unsure 50 % 38 % 0 % 30 % 0 %
DE GP (n = 4) Antenatal (n = 36) Asylum (n = 3) SHS (n = 5) Specialist (n = 9)
Yes 50 % 11 % 67 % 60 % 67 %
No 0 % 25 % 33 % 0 % 0 %
Unsure 50 % 64 % 0 % 40 % 33 %
NL GP (n = 9) Antenatal (n = 6) Asylum (n = 4) SHS (n = 8) Specialist (n = 22)
Yes 89 % 33 % 75 % 63 % 100 %
No 0 % 50 % 25 % 13 % 0 %
Unsure 11 % 17 % 0 % 25 % 0 %
HU GP (n = 1) Antenatal (n = 4) Asylum (n = 3) SHS (n = 3) Specialist (n = 10)
Yes 100 % 50 % 33 % 0 % 80 %
No 0 % 25 % 33 % 100 % 0 %
Unsure 0 % 25 % 33 % 0 % 20 %
IT GP (n = 14) Antenatal (n = 25) Asylum (n = 3) SHS (n = 1) Specialist (n = 9)
Yes 79 % 28 % 0 % 0 % 44 %
No 7 % 52 % 100 % 100 % 33 %
Unsure 14 % 20 % 0 % 0 % 22 %
ES GP (n = 2) Antenatal (n = 8) Asylum (n = 1) SHS (n = 2) Specialist (n = 4)
Yes 50 % 75 % 0 % 50 % 100 %
No 50 % 25 % 100 % 0 % 0 %
Unsure 0 % 0 % 0 % 50 % 0 %
Table 5 Identification of general guidelines by health professionals in relation to the perceived availability of training
Health professionals reporting that training is available
for professionals
UK DE NL HU IT ES Tot
Health professionals
mentioning hepatitis B
guidelines
15/25
(60 %)
14/17
(82 %)
34/40
(85 %)
7/12
(58 %)
13/22
(59 %)
5/12
(42 %)
88/128
(69 %)
Health professionals
mentioning hepatitis C
guidelines
15/25
(60 %)
12/17
(71 %)
29/40
(73 %)
8/12
(67 %)
13/22
(59 %)
5/12
(42 %)
82/128
(64 %)
Health professionals reporting that training is not
available for professionals or who were unsure
UK DE NL HU IT ES Tot
Health professionals
mentioning hepatitis B
guidelines
7/13
(54 %)
12/34
(35 %)
4/8
(50 %)
5/7
(71 %)
16/28
(57 %)
1/5
(20 %)
45/95
(47 %)
Health professionals
mentioning hepatitis C
guidelines
8/13
(62 %)
8/34
(24 %)
4/8
(50 %)
4/7
(57 %)
16/28
(57 %)
0/5
(0 %)
40/95
(42 %)
Public health professionals’ responses were not taken into consideration, since the question on the availability of training was not asked in the survey aimed at
public health professionals
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patients to seek care until the disease has progressed to
end-stage liver disease or hepatocellular carcinoma. On
the other hand, patients’ lack of knowledge about the
disease, language difficulties, lack of social support and
lack of understanding of the healthcare system contrib-
ute to the exclusion from health care of migrants from
endemic areas, despite current evidence showing that
they account for one of the largest HBV- or HCV-
infected group in Europe [45]. Legal, administrative,
financial barriers and the stigmatization of certain at-risk
groups, such as sex workers or PWID, also represent
major obstacles to an effective clinical management of
this condition [46, 47]. Models show that, with treat-
ment at current levels, mortality related to HCV is
expected to rise and to peak around 2030 [48]. Cohen et
al. recently introduced the concept of “under-treatment”
to refer to the disparity between the number of chronic-
ally infected individuals and the number of patients re-
ceiving treatment [12]. In order for chronic viral
hepatitis-related morbidity and mortality to stop to rise
in Europe, large increases in early detection and treat-
ment of patients are urgently needed.
Our study set out to measure availability and awareness
of two important means through which evidence-based
recommendations can influence clinical practice and HPs’
action towards effective clinical management, i.e. guide-
lines and training. Availability of general hepatitis guide-
lines was most commonly reported by HPs for whom
professional training is also available in their country. En-
couragingly, we identified a total of 53 national hepatitis B
or C guidelines and guidance documents, with examples
across the six countries. However, just twelve of these
were retrieved via the literature search. For Hungary,
the search failed to retrieve any guidelines published in
English, however seven guidelines, all in Hungarian,
were retrieved via the online survey. Moreover, in
accordance with prior studies [17–21], few HPs themselves
identified guidelines published in the scientific literature.
These findings suggest that the scientific databases are not
the most important information source of best clinical
practice for many HPs. Interestingly, more public health
officials identified specific guidelines for GPs than GPs
themselves. Limited guidance available was perceived
as a reason for inadequate referral of patients accord-
ing to sizeable proportions of HPs in all countries, with
the exception of Hungary. More comprehensive guide-
lines, tailored to the needs of specific professional
groups like GPs, sexual health or maternity services,
may be an alternative to increase awareness and improve
implementation of recommendations. Our findings
also indicate that there is either scarcity or complete
lack of guidance for HPs about screening practices and
disease management of migrants and asylum seekers
from endemic areas.
Results on the availability of specific hepatitis B/C train-
ing programmes suggest that, for many professionals, in
the Netherlands, the UK, Hungary and Spain training is
available. However there are differences between profes-
sional groups within countries. Results in the UK suggest
that training is lacking or unknown for GPs and profes-
sionals in health care for asylum seekers. In Germany,
training is similarly neither widespread nor well known
across all professional groups. In Hungary, training is not
widely available, especially for professionals working in the
area of sexual health. In Italy, a lack of availability was
reported by over half of the antenatal care providers and
by all respondents to the asylum seeker and SHS survey;
training seems to be more available to GPs. The low num-
bers of respondents among some professional groups in
Hungary and Spain limit the generalizability of findings,
although in Spain, training seems to be available for ante-
natal care providers and specialists.
That training is most commonly available to secondary
care specialists is perhaps not surprising; what is more
Table 6 Health professionals’ opinion on the existence of barriers as explanations of why hepatitis B/C cases do not reach
specialized health care (e.g. hepatologists) for further investigation and treatment. Results are presented by country
UK
(n = 47)
DE
(n = 64)
NL
(n = 55)
HU
(n = 21)
IT
(n = 58)
ES
(n = 23)
There is limited guidance available to primary
health care professionals about onward referral,
counselling and patient management of
hepatitis B/C patients.
Strongly disagree 11 % 8 % 2 % 33 % 7 % 17 %
Disagree 32 % 31 % 58 % 29 % 34 % 39 %
Neither agree or disagree 30 % 38 % 18 % 33 % 16 % 13 %
Agree 21 % 20 % 18 % 5 % 40 % 30 %
Strongly agree 6 % 3 % 4 % 0 % 3 % 0 %
Although training on viral hepatitis management
is available for health care providers, uptake is
generally low among professionals.
Strongly disagree 2 % 8 % 2 % 29 % 3 % 13 %
Disagree 23 % 31 % 9 % 24 % 21 % 43 %
Neither agree or disagree 36 % 45 % 56 % 33 % 22 % 35 %
Agree 34 % 16 % 31 % 10 % 52 % 9 %
Strongly Agree 4 % 0 % 2 % 5 % 2 % 0 %
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surprising is that less than half in Italy and only two
thirds of specialists in Germany reported the availability
of training. Given the role of the specialists and the rap-
idly advancing knowledge of viral hepatitis, especially
the new treatment options for hepatitis C, this finding
is particularly concerning. Results suggest that, except
for Spain, training for antenatal care providers is rather
limited, but especially so in Germany, Netherlands and
Italy. The implications of this could be sub-optimal
care and ineffective referral of pregnant women testing
positive, as well as a lack of contact tracing. It would be
particularly interesting to know how this lack of training
has an impact on the care of hepatitis B positive pregnant
women. Low training uptake as a possible explanation of
why hepatitis B/C cases do not reach specialized health
care was reported by relevant proportions of HPs in Italy,
in the UK, and in the Netherlands.
The findings from our study highlighted that the
awareness of screening and patient management guide-
lines and in-service training courses among HPs are
presently insufficient. Improving results, as supported
by key stakeholders [49], would imply a strong involve-
ment of national health authorities with the implemen-
tation of specific national action plans, an effective
disease surveillance to develop effective policies and
the establishment of specialized centers. In this respect,
the undeniable success of the experiences developed in
Scotland and in France provide a working model for
other countries to follow. Among the strategic actions
of the Hepatitis C Action Plan for Scotland [50], a
document was produced [51], with the aim to support
NHS Boards build action plans for facilitating, deliver-
ing and evaluating workforce education development
for staff. Complements this a workbook [52], published
to provide staff with a structured approach to assessing,
demonstrating and developing their ability to carry out
their role in delivering Hepatitis C services. Scaling up
HPs training and evaluating the compliance to clinical
practice guidelines were also objectives of the French Na-
tional Plan for hepatitis B and C 2009–2012, following
which the management of hepatitis B and C was set as a
priority topic in continuing medical education [53]. Subse-
quently, guidelines for the management of patients with
hepatitis B and C were developed [54], with recommenda-
tions aimed at HPs and the other key stakeholders.
Conclusions
Our results suggest that not only are there few exam-
ples of guidelines for the professional groups most able
to implement the recommendations, but also that there
is low awareness of those that do exist among primary
care professionals most often representing patients' first
points of contact. Without short, precise and feasible
guidelines, there are likely to be wide inconsistencies in
screening, referral and patient management. Results from
our survey also suggest that scientific databases are not
the most important information source of best clinical
practice for many HPs. Implementation of best practices
at both national and European level requires not only the
availability of high quality guidelines tailored to the needs
of the different professional groups, but also that their ex-
istence is actively promoted among those who are to fol-
low them, especially when we consider that availability of
research evidence alone does not necessarily coincide with
the adoption of recommended practices by physicians.
The availability of relevant summaries within guidelines,
as well as target dissemination to less experienced clini-
cians, along with the provision of clear and concise infor-
mation to patients, are possible solutions to enhance
guidelines implementation among clinicians. Given the
growing interest in knowledge translation and research
dissemination, our findings could prompt key decision-
making bodies to improve physicians’ awareness, agree-
ment, adoption and adherence to clinical practice guide-
lines, for example through professional associations and
training. Our results show that knowledge and availability
of hepatitis B/C training could also be improved. Further
studies assessing the impact of existing training and guide-
lines on the care, health literacy and onward referral of pa-
tients would be very valuable.
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